Company profile / AGARWALEYE

Dr. Agarwal's Health Care

Other · 2 quarters tracked · source-linked performance and management context.

Research layer active
PositiveCredibility 0/100Latest record q3-fy26

Latest revenue

₹530 Cr

verified financial record

Quarters tracked

2

source records in the directory

Delivery assessment

0

Across 2 tracked commitments: 0 delivered, 2 missed.

Call date

2026-02-10

latest available source date

Signal trajectory

2 actual quarters
Revenue (₹ Cr)PositiveWatchNegative
2 actual records
Actual quarterly Revenue (₹ Cr) trajectoryReported values plotted by quarter. Hover or focus a point for its quarter, value, and source sentiment.Q1 FY26: 487.3 · Positive source sentiment · 2025-08-14Q1 FY26Q3 FY26: 530 · Positive source sentiment · 2026-02-10Q3 FY26530487.3
Values are taken from the available verified source records; sentiment color is a separate source-read indicator.

Current read

0/100

Across 2 tracked commitments: 0 delivered, 2 missed.

Latest source read

What changed this quarter?

Open quarter read

Dr. Agarwal's Health Care delivered a strong Q3 FY26 with revenue from operations growing 23% YoY to ₹530 crore, driven by volume and value growth. EBITDA grew 21.3% YoY to ₹155 crore with margins stable at 28.4%, while PAT surged 55% YoY to ₹44 crore aided by lower finance costs. Surgical volumes grew 11.6% YoY, with high-end cataract procedures rising to 28% of cataract revenue and robotic cataract surgeries up 83% YoY. The company added 38 new facilities in 9M FY26 and plans 16 more in Q4, targeting 55-60 annual additions. Management reiterated confidence in meeting full-year guidance. Key risk: slower-than-expected ramp-up in newer geographies like Delhi and Ethiopia could pressure near-term margins.

Colored figures compare against the previous available record. Hover or focus one for the comparison.

Signal

Positive

Revenue

₹530 Cr

Source date

2026-02-10

Across the record

Quarter history.

2 source records

History modules

Follow the numbers and themes.